Drug intelligence / Profile preview

OP001F

Development stage: Preclinical
Lead developer: Osteo Pharma
Modality: Small Molecules
Administration: Local Implantation

Overview

OP001F (OsteoActivator-F) is a Class 3 medical device developed by Osteo-Pharma for the treatment of bone fractures. It consists of a biodegradable collagen barrier membrane coated with the proprietary OsteoActivator technology. This technology utilizes a biodegradable PLGA carrier to provide the sustained release of two low molecular weight compounds: testosterone, which promotes bone formation, and alendronate, which inhibits bone resorption. The device is designed for local implantation at fracture sites to facilitate guided bone regeneration and enhance the natural healing process over a period of 4 to 6 weeks.

Brand names: OsteoActivator-F
Other names: OsteoActivator-F (OP001F)

Targets

AR (Adrenergic receptors)FDPS (Farnesyl pyrophosphate synthase)

Beyond the preview

Go deeper on OP001F.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OP001F.

Explore the full profile